Position
Fidelity in Moonlake Immunotherapeutics
Back to the book · All holders of MLTX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $119.2K$18.64 → $19.47
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 156.3K | $2.06M | — | — | — | 0.0% |
| Q1 2026 | 143.6K | $2.68M | $18.64 | $783.8K | −$167.6K | 0.0% |
| Q2 2026 | 143.6K | $2.8M | $19.47 | $119.2K | $0 | 0.0% |